 |
 |
 |
| May 30, 2002 |
Taisho Launches Avalon Z |
|||||||||||||||||||||||||||||||||||
 (left:Avalon Z,right:Avalon S) |
|||||||||||||||||||||||||||||||||||
Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) launched sales of Avalon Z, a general purpose stomach medication containing the histamine H2 blocker Ranitidine and ingredients to neutralize gastric acids, on June 3, 2002. Avalon Z is formulated with the histamine H2 blocker Ranitidine as well as three active ingredients that neutralize gastric acids, including magnesium aluminosilicate. The three antacids neutralize excessive acids produced in the stomach, while the H2 blocker controls their secretion. The result is outstanding effectiveness for those suffering from gastric pains. Taisho Pharmaceutical’s Taisho Kanpo Ichoyaku, which was released in 1978, has won strong support from gastric medication customers as a self-medication product with improved functions. In fact, it is now is the leading brand of general gastric medication. In recent years, more people have been suffering gastric distress, and demand for general purpose stomach medications is diversifying. In response, in 1998, Taisho switched Sofalcone, the gastric mucosa repair agent it had developed, from prescription drug to self-medication use and launched Avalon S, a gastric medication that is highly regarded. To build the Avalon brand into a series of gastric pain medications to meet a wider range of consumer needs, Taisho has now strengthened the line by launching Avalon Z with a histamine H2 blocker. |
|||||||||||||||||||||||||||||||||||
|
Product features
|
|||||||||||||||||||||||||||||||||||
Product Overview
|
|||||||||||||||||||||||||||||||||||
